• In early August 2026, Tandem Diabetes Care reported second-quarter 2026 results showing sales of US$254.56 million, a reduced net loss of US$21.17 million, and significantly lower basic loss per share compared with the same period a year earlier.
• The company also reaffirmed its full-year 2026 sales outlook of US$1.07–1.09 billion while highlighting early traction of its Pay-As-You-Go pharmacy model, growing Mobi platform adoption, and progress toward FDA clearance for new tubeless capabilities.
• We’ll now examine how reaffirmed full-year sales guidance and early Pay-As-You-Go traction may influence Tandem Diabetes Care’s investment narrative.

AI is about to change healthcare. These 43 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Tandem Diabetes Care Investment Narrative Recap

To own Tandem Diabetes Care, you need to believe insulin pumps and automated delivery will keep gaining share and that Tandem can convert that demand into profitable, recurring revenue. Right now, the key near term catalyst is broader adoption of its Pay As You Go pharmacy model, while the biggest risk is intensifying competition that could slow new pump starts. The latest results modestly support the catalyst, but do not remove the competitive pressure risk.

The reaffirmed full year 2026 sales outlook of US$1.065–1.085 billion is the most relevant announcement here, because it brackets how management currently sees the Pay As You Go rollout, Mobi adoption, and upcoming tubeless features affecting revenue this year. With pharmacy shipments already about 10% of US shipments and formulary coverage around 45%, this guidance helps frame how quickly these catalysts might show up in reported numbers.

However, behind the improving numbers, investors should be aware of the risk that growing reliance on the pharmacy channel could expose Tandem to shifting reimbursement and pricing pressure that...

Tandem Diabetes Care's narrative projects $1.4 billion revenue and $63.4 million earnings by 2029. This requires 10.3% yearly revenue growth and a $157.9 million earnings increase from -$94.5 million today.

Uncover how Tandem Diabetes Care's forecasts yield a $29.20 fair value, a 30% upside to its current price.

Exploring Other Perspectives

The most optimistic analysts already expected revenue of about US$1.6 billion and earnings near US$171 million by 2029, so this quarter’s Pay As You Go progress may strengthen or challenge that view depending on how you weigh faster pharmacy margin gains against the risk that reimbursement changes could squeeze those same margins over time.

Explore 3 other fair value estimates on Tandem Diabetes Care - why the stock might be worth over 3x more than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Tandem Diabetes Care research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Tandem Diabetes Care research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Tandem Diabetes Care's overall financial health at a glance.

Interested In Other Possibilities?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• Find 51 companies with promising cash flow potential yet trading below their fair value.
• Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• The future of work is here. Discover the 36 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.